Abbott Neuromodulation operates the deep brain stimulation and spinal cord stimulation businesses acquired from St. Jude Medical in 2017 for $25 billion. The Infinity DBS system was the first FDA-approved directional DBS device (2016) and features patient-controlled programming via iPhone. Abbott competes directly with Medtronic and Boston Scientific in the approximately $2B annual DBS market, differentiating on directional stimulation precision and smartphone connectivity.